Concomitant pharmacologic medications influence the clinical outcomes of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis: A multicenter retrospective cohort study.
biologics
clinical remission
granulocyte and monocyte apheresis
immunosuppressors
loss of response
negative factor
positive factor
ulcerative colitis
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
20
09
2022
received:
22
07
2022
accepted:
27
12
2022
medline:
6
7
2023
pubmed:
14
1
2023
entrez:
13
1
2023
Statut:
ppublish
Résumé
Granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn has been used as a remission induction therapy for patients with active ulcerative colitis (UC). Herein, we investigated the influence of concomitant medications in the remission induction of GMA in patients with active UC. This multicenter retrospective cohort study included patients with UC underwent GMA in five independent institutions in Japan from January 2011 to July 2021. Factors including concomitant medications associated with clinical remission (CR) were analyzed statistically. A total of 133 patients were included. Seventy-four patients achieved a CR after GMA. The multivariable analysis revealed that concomitant medication with 5-aminosalicylic acid, Mayo endoscopic subscore (MES), and concomitant medication with immunosuppressors (IMs) remained as predictors of CR after GMA. In the subgroup analysis in patients with MES of 2, concomitant medication with IMs was demonstrated as a significant negative factor of CR after GMA (P = .042, OR 0.354). Seventy-four patients who achieved CR after GMA were followed up for 52 weeks. In the multivariable analysis, the maintenance therapy with IMs was demonstrated as a significant positive factor of sustained CR up to 52 weeks (P = .038, OR 2.214). Furthermore, the rate of sustained CR in patients with biologics and IMs was significantly higher than that in patients with biologics only (P = .002). GMA was more effective for patients with active UC that relapsed under treatment without IMs. Furthermore, the addition of IMs should be considered in patients on maintenance therapy with biologics after GMA.
Sections du résumé
BACKGROUND
BACKGROUND
Granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn has been used as a remission induction therapy for patients with active ulcerative colitis (UC). Herein, we investigated the influence of concomitant medications in the remission induction of GMA in patients with active UC.
METHODS
METHODS
This multicenter retrospective cohort study included patients with UC underwent GMA in five independent institutions in Japan from January 2011 to July 2021. Factors including concomitant medications associated with clinical remission (CR) were analyzed statistically.
RESULT
RESULTS
A total of 133 patients were included. Seventy-four patients achieved a CR after GMA. The multivariable analysis revealed that concomitant medication with 5-aminosalicylic acid, Mayo endoscopic subscore (MES), and concomitant medication with immunosuppressors (IMs) remained as predictors of CR after GMA. In the subgroup analysis in patients with MES of 2, concomitant medication with IMs was demonstrated as a significant negative factor of CR after GMA (P = .042, OR 0.354). Seventy-four patients who achieved CR after GMA were followed up for 52 weeks. In the multivariable analysis, the maintenance therapy with IMs was demonstrated as a significant positive factor of sustained CR up to 52 weeks (P = .038, OR 2.214). Furthermore, the rate of sustained CR in patients with biologics and IMs was significantly higher than that in patients with biologics only (P = .002).
CONCLUSION
CONCLUSIONS
GMA was more effective for patients with active UC that relapsed under treatment without IMs. Furthermore, the addition of IMs should be considered in patients on maintenance therapy with biologics after GMA.
Substances chimiques
Biological Products
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-421Informations de copyright
© 2023 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals LLC.
Références
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619. doi:10.1016/S0140-6736(12)60150-0
Hanai H, Takeda Y, Eberhardson M, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163(1):50-58. doi:10.1111/j.1365-2249.2010.04279.x
Hibi T, Sameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41(8):570-577. doi:10.1016/j.dld.2008.11.020
Kruis W, Dignass A, Steinhagen-Thiessen E, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol. 2005;11(44):7001-7006. doi:10.3748/wjg.v11.i44.7001
Passalacqua S, Ferraro PM, Bresci G, et al. The Italian registry of therapeutic apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease: a multicentric study. J Clin Apher. 2011;26(6):332-337. doi:10.1002/jca.20315
Sacco R, Romano A, Mazzoni A, et al. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis. 2013;7(12):e692-e697. doi:10.1016/j.crohns.2013.06.012
Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104(12):2990-2995. doi:10.1038/ajg.2009.453
Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135(2):400-409. doi:10.1053/j.gastro.2008.04.023
Yokoyama Y, Kawai M, Fukunaga K, et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. doi:10.1186/1471-230X-13-27
Iida T, Ikeya K, Kato M, et al. Adsorptive depletion of myeloid lineage leucocytes as remission induction therapy in patients with ulcerative colitis after failure of first-line medications: results from a three-year real world, clinical practice. Digestion. 2017;96(2):119-126. doi:10.1159/000479502
Yamamoto T, Iida T, Ikeya K, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis [published correction appears in Clin Transl Gastroenterol. 2018;9(10):192] [published correction appears in Clin Transl Gastroenterol. 2018;9(11):205]. Clin Transl Gastroenterol. 2018;9(7):170. doi:10.1038/s41424-018-0037-0
Ishiguro Y, Ohmori T, Umemura K, et al. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: a multicenter cohort study. Ther Apher Dial. 2021;25(4):502-512. doi:10.1111/1744-9987.13594
Yokoyama Y, Watanabe K, Ito H, et al. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy. 2015;17(5):680-688. doi:10.1016/j.jcyt.2015.02.007
Kakimoto K, Matsuura M, Fukuchi T, et al. Exploratory study of the effectiveness of granulocyte and monocyte adsorptive apheresis before initiation of steroids in patients with active ulcerative colitis (EXPECT study): a multicenter prospective clinical trial. Crohns Colitis 360. 2020;2(4):otaa073. doi:10.1093/crocol/otaa073
Imperiali G, Amato A, Terpin MM, et al. Granulocyte-monocyte apheresis in steroid-dependent, azathioprine-intolerant/resistant moderate ulcerative colitis: a prospective multicenter study. Gastroenterol Res Pract. 2017;2017:9728324. doi:10.1155/2017/9728324
Dignass A, Akbar A, Baumgart DC, et al. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53(4):442-448. doi:10.1080/00365521.2018.1447598
Tanida S, Ozeki K, Kanno T, et al. Combination therapy with ustekinumab plus intensive granulocyte and monocyte adsorptive apheresis in patients with refractory ulcerative colitis. J Clin Med Res. 2021;13(10-11):510-514. doi:10.14740/jocmr4625
Song A, Jiang H, Guo L, Wu S. The combined efficacy of adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion. Am J Transl Res. 2021;13(5):5156-5164.
Nakamura M, Yamamura T, Maeda K, et al. Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis. Intern Med. 2020;59(23):3009-3014. doi:10.2169/internalmedicine.5302-20
Rodríguez-Lago I, Benítez JM, Sempere L, et al. The combination of granulocyte-monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis? J Clin Apher. 2019;34(6):680-685. doi:10.1002/jca.21746
Tanida S, Ozeki K, Mizoshita T, et al. Combination therapy with tofacitinib plus intensive granulocyte and monocyte adsorptive apheresis as induction therapy for refractory ulcerative colitis. J Clin Med Res. 2020;12(1):36-40. doi:10.14740/jocmr4037
Rodríguez-Lago I, Sempere L, Gutiérrez A, et al. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scand J Gastroenterol. 2019;54(4):459-464. doi:10.1080/00365521.2019.1600715
Yokoyama Y, Sawada K, Aoyama N, et al. Efficacy of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease showing lost response to infliximab. J Crohns Colitis. 2020;14(9):1264-1273. doi:10.1093/ecco-jcc/jjaa051
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-1629. doi:10.1056/NEJM198712243172603 PMID: 3317057.
Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-1201. doi:10.1053/j.gastro.2011.06.054
Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393-407.
Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021 Jun;56(6):489-526. doi:10.1007/s00535-021-01784-1
Ueno N, Sugiyama Y, Kobayashi Y, et al. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol. 2021;21(1):316. doi:10.1186/s12876-021-01889-0
Matsuda K, Ohno K, Okada Y, et al. Adsorptive granulocyte and monocyte apheresis is effective in ulcerative colitis patients both with and without concomitant prednisolone. Inflamm Intest Dis. 2020;5(1):36-41. doi:10.1159/000505484
Hiraishi K, Takeda Y, Shiobara N, et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial. 2003;7(3):334-340. doi:10.1046/j.1526-0968.2003.00049.x
Kanekura T, Hiraishi K, Kawahara K, Maruyama I, Kanzaki T. Granulocyte and monocyte adsorption apheresis (GCAP) for refractory skin diseases caused by activated neutrophils and psoriatic arthritis: evidence that GCAP removes Mac-1-expressing neutrophils. Ther Apher Dial. 2006;10(3):247-256. doi:10.1111/j.1744-9987.2006.00369.x
Takeda Y, Shiobara N, Saniabadi AR, et al. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and beta2 integrin. Inflamm Res. 2004;53(7):277-283. doi:10.1007/s00011-004-1253-5
Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008;40(9):731-736. doi:10.1016/j.dld.2008.02.012
Takeda S, Sato T, Katsuno T, et al. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci. 2010;55(7):1886-1895. doi:10.1007/s10620-009-0974-2
Hanai H, Iida T, Takeuchi K, et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103(5):1210-1216. doi:10.1111/j.1572-0241.2007.01714.x
Saas P, Bonnefoy F, Toussirot E, Perruche S. Harnessing apoptotic cell clearance to treat autoimmune arthritis. Front Immunol. 2017;8:1191. doi:10.3389/fimmu.2017.01191
Ansary MM, Ishihara S, Oka A, et al. Apoptotic cells ameliorate chronic intestinal inflammation by enhancing regulatory B-cell function. Inflam Bowel Dis. 2014;20(12):2308-2320. doi:10.1097/MIB.0000000000000240
Saniabadi AR, Tanaka T, Yamamoto T, et al. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34(1):51-60. doi:10.1002/jca.21670
Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191(3):411-416. doi:10.1084/jem.191.3.411
Kushwah R, Hu J. Role of dendritic cells in the induction of regulatory T cells. Cell Biosci. 2011;1(1):20. doi:10.1186/2045-3701-1-20
Campbell DJ. Control of regulatory T cell migration, function, and homeostasis. J Immunol. 2015;195(6):2507-2513. doi:10.4049/jimmunol.1500801
Matsuoka K. NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease. Intest Res. 2020;18(3):275-281. doi:10.5217/ir.2020.00002
Carter M, Jemth AS, Hagenkort A, et al. Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2. Nat Commun. 2015;6:7871. doi:10.1038/ncomms8871
Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.e3. doi:10.1053/j.gastro.2013.10.052